John Wetterau - Langhorne PA, US Daru Sharp - Perrineville NJ, US Richard Gregg - Pennington NJ, US Scott Biller - Ewing NJ, US John Dickson - Mount Holly NJ, US R. Lawrence - Yardley PA, US John Lawson - Wallingford CT, US Henry Holava - Meriden CT, US Richard Partyka - Neshanic NJ, US
International Classification:
A61K048/00 C07H021/04
US Classification:
514/044000, 536/023200
Abstract:
Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.
John R. Wetterau - Langhorne PA Daru Young Sharp - Perrineville NJ Richard E. Gregg - Pennington NJ
Assignee:
E. R. Squibb & Sons, Inc. - Princeton NJ
International Classification:
C12P 2102 C07K 1400 C12Q 100 C12Q 125
US Classification:
435 691
Abstract:
Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.
Nucleic Acids Encoding Microsomal Trigyceride Transfer Protein
John R. Wetterau - Langhorne PA Daru Y. Sharp - Perrineville NJ Richard E. Gregg - Pennington NJ Scott A. Biller - Ewing NJ John K. Dickson - Mount Holly NJ R. Michael Lawrence - Yardley PA John E. Lawson - Wallingford CT Henry M. Holava - Meriden CT Richard A. Partyka - Neshanic NJ
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C12Q 170 C07H 2102 C12N 1579 C12N 510
US Classification:
435 6
Abstract:
Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.
Lombardy Elementary School Pharmaceuticals · High School · Elementary School
412 Foulk Rd, Wilmington, DE 19803 1400 Foulk Rd, Wilmington, DE 19803 3024791600, 3027627190, 3027627108
Richard Gregg Supervisor
City of Newark Executive Office · Executive/Legislative Combined · Land/Mineral/Wildlife Conservation Amusement/Recreation Services · Water Department · Police Protection
220 Elkton Rd, Newark, DE 19711 3023667000, 3023667020, 3023667060, 3023667055
Anesthesia Associates Of Cincinnati 2139 Auburn Ave Lvl A, Cincinnati, OH 45219 5135852422 (phone), 5135853245 (fax)
Education:
Medical School University of Louisville School of Medicine Graduated: 1981
Languages:
English
Description:
Dr. Gregg graduated from the University of Louisville School of Medicine in 1981. He works in Cincinnati, OH and specializes in Anesthesiology. Dr. Gregg is affiliated with Christ Hospital.
No one outside of the staff doing the work ever asked to have access to the payment files, said Richard Gregg, who spent four decades working for Treasury and oversaw the payment system as fiscal assistant secretary.
Date: Feb 03, 2025
Category: U.S.
Source: Google
Vitae Pharma shares spike on positive trial results
Vitae plans to advance the tests to a broader 16-week trial in the second half of the 2016 "to continue to asses the efficacy, safety and tolerability" of the medication, Richard Gregg, the company's chief scientific officer, said in a statement issued with the announcement.
Date: Mar 17, 2016
Category: Business
Source: Google
Vitae Pharma (VTAE) Announces Statistically Significant Data from VTP-43742 Phase 2a PoC Trial in Psoriatic Patients
We plan to advance VTP-43742 into a larger scale 16 week trial in the second half of 2016 to continue to assess the efficacy, safety and tolerability of our first-in-class drug candidate, said Dr. Richard Gregg, Chief Scientific Officer of Vitae. We look forward to presenting the complete results
Date: Mar 16, 2016
Category: Business
Source: Google
2 held in deadly South Dade drive-by collaborated once before
Theres been an outpouring of support for him. Hes soft spoken and well mannered, said his lawyer, Richard Gregg. From what hes told me, he is not the shooter and had no direct involvement in the shooting of the house. I believe he will be vindicated.
Date: Dec 29, 2015
Source: Google
Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending ...
"The initiation of this Phase 1 study of our wholly owned first-in-classRORt inhibitor is a very important milestone both for Vitae and for patients afflicted with autoimmune disorders," said Dr. Richard Gregg, Chief Scientific Officer of Vitae. "We believe that VTP-43742's unique mechanism of act
Date: Jun 29, 2015
Source: Google
Vitae suffers another stinging setback as lead diabetes drug fails in PhII
"The metabolically complex, overweight type 2 diabetic patient population is in need of novel mechanisms of action that can address their overall risk profile," said Dr. Richard Gregg, the CSO of Vitae, in a statement. "We are anxious to learn more about BI187004/VTP-34072 when the study is complete
Now, about 85% of Social Security beneficiaries get payments through direct deposit, says Treasury assistant secretary Richard Gregg. But the government issues more than 120 million checks a year, at a cost of about $1 each, vs. 10 cents for an electronic payment, Gregg says. Treasury estimates that